With 20 years’ experience in the Johnson & Johnson (JNJ) Board Room as a C-Suite executive, Mike Ullmann is a seasoned global leader with extensive experience in the Life Sciences. Ullmann served as the Executive Vice President, General Counsel and Executive Committee Member of JNJ for 11 years from January 2012 until his retirement at the end of 2022. As General Counsel of the world's largest Life Sciences company, he successfully guided JNJ through high-profile and high-risk situations, while enabling business growth and increasing shareholder value. Ullmann led a global organization of over 2,000 employees in 60 countries encompassing Legal, Government Relations & Policy, ESG Strategy, Intellectual Property, Corporate Governance and the Risk Management areas of Data Privacy, Compliance and Security. In his EVP role, he also played a critical role in over 100 M&A transactions (totaling over $100 billion).Starting at JNJ in 1989, Ullmann held a series of senior leadership positions across JNJ demonstrating the ability to successfully lead across a global scale of a diverse range of regulated Life Sciences businesses in biotechnology, pharmaceuticals, consumer products, medical devices, diagnostics and vision care. In the non-profit world, Ullmann serves as a Director and Audit Committee Chair of Americares, the global healthcare and relief organization with over $1.5 billion provided in program services annually.  He also serves as a Board member and Executive Committee member of the Princeton Area Community Foundation.  In 2023, Ullmann joined the Board of the Naples Zoo, a nationally accredited zoo in Southwest Florida, which is also involved in conservation of wildlife and plants on a global basis.Since retiring from JNJ, Ullmann has also engaged in activities in the academic world related toinnovation, research and leadership. At Massachusetts Institute of Technology (MIT), he was appointed by MIT's President to the Visiting Committee for Sponsored Research, which serves as an advisory group on research activities sponsored by companies and the government.  He has also been appointed to the MIT Sandbox Innovation Fund Board, an incubator program to support MIT undergrad, graduate and postdoc students in the pursuit of their innovative and entrepreneurial ventures. Ullmann also serves as an Adjunct Faculty Member at Columbia Law School and has led workshops on ethical and values-based leadership at MIT and Columbia.In 2024, Ullmann joined the Board of Managers of Cytogel, a privately-held early stage biopharma company.